Spots Global Cancer Trial Database for Cancer Patients Treated With Immunotherapy in Intensive Care Unit
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Official Title: Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.
Study ID: NCT03357861
Interventions
Study Description
Brief Summary: This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.
Detailed Description: The place of checkpoint inhibitors (anti-PD-1 and PD-L-1) is currently validated in the management of melanoma and metastatic non-small cell lung cancer. The toxicity profile is specific with adverse effects related to immunity. Some side effects (myocarditis, colitis, interstitial lung disease, etc.) can be severe and patient could be hospitalized in intensive care unit. The question of immunotherapy's imputability in the acute disease is becoming more frequent.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institut Jules Bordet, Bruxelles, , Belgium
UniversityHospitalGrenoble, Grenoble, , France
Contact Details
Name: Anne-Claire TOFFART, MD-PhD
Affiliation: UniversityHospital Grenoble
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
